Skip to main content
Premium Trial:

Request an Annual Quote

Coimbra Genomics Joins Estonian Personalized Medicine Consortium

NEW YORK (GenomeWeb) – Portuguese genome-based clinical decision support systems developer Coimbra Genomics announced today that it has joined an international consortium on personalized medicine led by Estonia’s Competence Center on Health Technologies (CCHT).

The consortium — which includes members such as the University of Tartu's Estonian Genome Center, Tallinn University of Technology's eMedicine Laboratory, BioEximi OÜ, and Finland's Duodecim Medical Publications — will contribute to the Estonian Personalized Medicine Initiative, which aims to pilot the use of several personalized medicine tools in the clinic, Coimbra said in a statement.

Coimbra will participate in a study on the feasibility of using personalized medicine decision support systems. Its Elsie platform is designed to allow doctors everywhere to use patients' genomic information to make prognostic and prescriptive decisions in the setting of a regular medical appointment.

Finnish bioinformatics firm MediSapiens also recently announced it had joined the Estonian consortium, which is being co-financed by the European Regional Development Fund via Enterprise Estonia, the CCHT, and the consortium partners. The company is participating in a phase of the project to assess the necessary requirements for developing clinically valid and commercially viable personalized medicine products and services.

Estonia is one of the first countries to reimburse the cost of whole-exome sequencing in newborns for clinically relevant cases, Coimbra added.